Skip to main content
. 2020 Nov 23;12(1):1842990. doi: 10.1080/19490976.2020.1842990

Figure 5.

Figure 5.

Schematic diagram showing the possible mechanisms of anti-metabolic disorders (MDs) effects of phlorizin (PHZ). Other than the primary target of sodium-glucose co-transporters-2 (SGLT2), the ‘gut microbiota-barrier axis’, including the gut microbiota and the gut barrier, served as alternative targets for the beneficial action of PHZ. GLP: glucagon-like peptide; LPS: lipopolysaccharide; SCFAs: short-chain fatty acids